Aquestive Therapeutics, Inc. AQST

US Pharmaceuticals

$3.61 ▲ +1.98% (+$0.07)

🔥 High Short Interest

Open $3.51

Prev Close $3.54

Day Range $3.48 – $3.64

52W Range $2.93 – $6.85

Market Cap $444.93M

Beta 1.67

EPS (TTM) $-0.64

📋 Company Profile

Industry	Pharmaceuticals
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2018-07-25
Shares Out.	125,510,000
Website	aquestive.com/ ↗
Phone	13026365400
Employees	147
Revenue	$7.6M
Gross Profit	$4.0M
Net Income	-$16.5M
Free Cash Flow	-$40.7M
Total Assets	$119.3M
Total Liabilities	$190.2M
Equity	-$70.8M

About Aquestive Therapeutics, Inc.

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

Aquestive Therapeutics, Inc. is a publicly traded company under the ticker symbol AQST on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.